[1] 宋飞艳,程蕾蕾. 超声心动图监测淋巴瘤患者蒽环类药物化疗后右心室亚临床功能减退的应用[J].复旦学报:医学版, 2016, 43(2):231-235. [2] Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity:the value of considering both global longitudinal left ventricular strain and twist[J].Canadian J Physiol Pharmacol,2013,91(8):601-607. [3] 马军, 秦叔逵, 沈志祥. 蒽环类药物心脏毒性防治指南(2013年版)[J].临床肿瘤学杂志,2013,18(10):925-934. [4] Colombo A,Cardinale D. Using cardiac biomarkers and treating cardiotoxicity in cancer[J]. Future Cardiol, 2013, 9(1):105-118. [5] Urun Y,Utkan G,Yalcin B,et al.The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer[J]. Exp Oncol, 2015, 37(1):53-57. [6] 宋飞艳, 程蕾蕾, 史静,等. 二维斑点追踪显像联合实时三维超声心动图监测淋巴瘤患者蒽环类药物化疗后左心室亚临床功能的改变[J]. 中华超声影像学杂志, 2016, 25(3):192-197,202. [7] 薛继平,苏莉莉,康春松,等. 斑点追踪技术评价蒽环类药物对乳腺癌患者左心室跨壁力学的影响[J]. 中华超声影像学杂志, 2015,24(12):1033-1038. [8] 毕小军, 邓又斌, 曾繁静, 等. 二维应变超声心动图评价乳腺癌患者表阿霉素化疗后左心室收缩功能[J].中国医学影像技术,2009,25(8):1415-1418. [9] 洪少杰,林树洪,于瑞芳,等. 超声二维斑点追踪技术监测蒽环类药物治疗恶性淋巴瘤后心脏功能变化[J]. 肿瘤学杂志, 2017, 23(1):49-53. [10] Wasle I, Gamerith G, KocherF, et al. Non-pegylated liposomal doxorubicin in lymphoma:patterns of toxicity and outcome in a large observational trial[J].Anna Hematol, 2014, 94(4):593-601. [11] Neri N, Avilés A, SchmittCJ, et al. Aggressive chemotherapy in frail patients with diffuse large B-cell lymphoma:The role of pegylated liposomal doxorubicin[J].J Hematol Malign, 2012, 2(2):58-62. [12] Hunault-Berger M,Leguay T, Thomas X,et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia:the GRAALL-SA1 study[J].Haematologica, 2013, 96(2):245-252. [13] Sawaya H, Sebag IA, PlanaJC,et al.Early detection and prediction of cardiotoxicity in chemotherapy-treated patients[J]. Am J Cardiol, 2011, 107(9):1375-1380. [14] Katsurada K, Ichida M, Sakuragi M,et al. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy[J].Springerplus, 2014, 3:620. [15] Al-Kindi S, Younes A, QattanM,et al. Preemptive cardioprotective strategies in patients receiving chemotherapy GH oliveira[J].Curr Cardiovasc Risk Rep, 2014, 8(11):406-409. |